Treatment outcomes of adult B-cell ALL with post-transplant relapse in the era of immunotherapeutic agents - PubMed
3 hours ago
- #B-cell ALL
- #Post-transplant relapse
- #Immunotherapy outcomes
- Outcomes improved in Ph-negative adult B-cell ALL after post-transplant relapse with immunotherapies (inotuzumab ozogamicin and blinatumomab), showing a rise in 2-year overall survival from 19% to 51% and complete remission rates from 36% to 77%.
- Safety profiles for these agents in the post-transplant setting were acceptable, with specific concerns noted for VOD/SOS in patients undergoing a second transplant after inotuzumab, especially with a short interval (<2.5 months).
- No significant survival improvement was observed in Ph-positive ALL patients, indicating differential impact based on genetic subtype.
- The study highlights the importance of timing and disease status at first transplant as prognostic factors, supporting the integration of these immunotherapies into treatment strategies for relapsed cases.